Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention

Athyros, Vasilios G.; Katsiki, Niki; Karagiannis, Asterios; Mikhailidis, Dimitri P.

doi:10.1185/03007995.2014.954666

Cited by 12 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statin use is acknowledged to be beneficial to patients after AMI through 'pleiotropic mechanisms' additional to the ability of the treatment to lower low-density lipoprotein cholesterol levels (4,5). The results of the present study demonstrated that long-term statin use prior to AMI improves clinical outcomes after PPCI, despite a substantially higher risk profile in the statin group.…”

Section: Discussionmentioning

confidence: 50%

“…It is well established that statin treatment is beneficial for the primary and secondary prevention of coronary artery diseases (3,4). In addition to lowering serum lipid levels, statins have been shown to convey favorable effects on endothelial function, coagulation activation, nitric oxide bioavailability and stimulation of the inflammatory response.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction

Guo¹,

Yang²,

Mu³

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Numerous studies have reported that high-dose statin loading therapy prior to primary percutaneous coronary intervention (PPCI) improves the clinical outcomes of patients following acute myocardial infarction (AMI). However, little is known about the effects of long-term statin use prior to PPCI on such outcomes. Therefore, the aim of the present analysis was to clarify the effects of long-term statin use before PPCI on the treatment outcomes of patients following AMI. The records of 213 patients who had AMI and met the inclusion criteria were retrospectively reviewed. Patients were divided into two groups: A control group (n=178) who had received no statin pretreatment before AMI onset, and a statin group (n=35) who had received statin treatment for ≥1 month before AMI onset. All patients received a standard treatment regimen for the secondary prevention of coronary artery disease after PPCI. Baseline clinical variables, details of the PPCI procedure and clinical outcomes within 3 months after treatment were reviewed. Patients in the statin group were significantly older than those in the control group (P=0.003). Compared with the control group, there was a greater proportion of patients with hyperlipidemia and previous angina pectoris in the statin group. There were no differences in the use of other drugs (aspirin, β-blockers and angiotensin-converting enzyme inhibitors) prior to PPCI between the two groups. The corrected TIMI frame count (cTFC) was significantly lower in the statin group than in the control group (24.1±12.8 vs. 29.4±14.3, respectively; P=0.043). Multivariable linear regression analysis showed that long-term statin use before AMI was a significant predictor of cTFC after PPCI (P=0.012).Furthermore, the incidence of major adverse cardiac events within 3 months after PPCI was higher in the control group than in the statin group (16.8 vs. 2.9%, respectively; P=0.032). Logistic regression analysis showed that previous statin use was associated with the incidence of major adverse cardiac events within 3 months after treatment (P=0.012). The results of the present study demonstrate that long-term statin use prior to PPCI improved treatment outcomes after AMI in actual clinical practice.

show abstract

Section: Discussionmentioning

confidence: 50%

Section: Introductionmentioning

confidence: 99%

Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction

Guo¹,

Yang²,

Mu³

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…However, these results were obtained from patients with ACS that are at higher CVD risk than those with stable CAD (Schwartz, Olsson, Ezekowitz, et al, 2001). Of note, peri-procedural high-intensity statin treatment in patients undergoing PCIs, either for an ACS or stable CAD, has been reported to significantly decrease short-, mid-, and long-term CVD morbidity and mortality as well as all-cause death rates than lower intensity statins or no statin treatment (Athyros, Katsiki, Karagiannis, & Mikhailidis, 2014c).…”

mentioning

confidence: 53%

High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus

Athyros

Katsiki

Karagiannis

et al. 2015

Journal of Diabetes and its Complications

Self Cite

View full text Add to dashboard Cite

“…Whereas some patients with CKD will finally develop ESRD, most of them will die of CVD before dialysis becomes necessary [108,109]. There are data suggesting that statin treatment, the cornerstone of primary and secondary prevention of CVD in patients with dyslipidaemia, might be helpful in dealing with CKD risk [29,[110][111][112][113][114][115][116][117][118][119].…”

Section: Expert Opinionmentioning

confidence: 99%

Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?

Athyros

Katsiki

Karagiannis

et al. 2015

Expert Opinion on Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

Current evidence points towards the need to prescribe high-potency statins in patients with CKD, before a major decline in kidney function occurs. This may reduce CVD risk and delay the progress of CKD. Administration of either atorvastatin or rosuvastatin can prevent contrast-induced AKI before angiography or percutaneous coronary intervention. The combination of simvastatin + ezetimibe may decrease vascular events in patients with advanced CKD.

show abstract

Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention

Cited by 12 publications

References 38 publications

Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction

Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction

High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus

Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?

Contact Info

Product

Resources

About